Related references
Note: Only part of the references are listed.Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Neil A. O'Brien et al.
CLINICAL CANCER RESEARCH (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
Ondrej Kalous et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Ondrej Kalous et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
B. Weigelt et al.
ONCOGENE (2011)
Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Interactome Mapping of the Phosphatidylinositol 3-Kinase-Mammalian Target of Rapamycin Pathway Identifies Deformed Epidermal Autoregulatory Factor-1 as a New Glycogen Synthase Kinase-3 Interactor
Fanny Pilot-Storck et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
Essential Roles of mTOR/Akt Pathway in Aurora-A Cell Transformation
Makoto Taga et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2009)
PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis
Babette Schade et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
mTOR signaling at a glance
Mathieu Laplante et al.
JOURNAL OF CELL SCIENCE (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells
Xianhui Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
Chien-Hsing Lu et al.
CLINICAL CANCER RESEARCH (2007)
Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer
Lin Zhang et al.
CLINICAL CANCER RESEARCH (2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
M. Beeram et al.
ANNALS OF ONCOLOGY (2007)
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2007)
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
Gizeh Perez-Tenorio et al.
CLINICAL CANCER RESEARCH (2007)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells (Publication with Expression of Concern. See vol. 144, 2019)
Hua Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation
X. Wang et al.
ONCOGENE (2006)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
Oliver Treeck et al.
GYNECOLOGIC ONCOLOGY (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers
XY Zhou et al.
CLINICAL CANCER RESEARCH (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
The cellular geography of aurora kinases
M Carmena et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Mitotic kinases as regulators of cell division and its checkpoints
EA Nigg
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
